yesnoWas this document useful for you?Thank you for your participation!

* Your assessment is very important for improving the work
of artificial intelligence, which forms the content of this project

1

2

Transcript

Embryonic stem cell
Embryonic stem cells
Pluripotent: Embryonic stem cells are able to develop into any type of cell, excepting those of the
placenta.
Embryonic stem cells (ESC) are pluripotent stem cells derived from the inner cell mass of a
blastocyst, an early-stage preimplantation embryo.[1][2] Sheep embryos reach the blastocyst stage
4–5 days post fertilization, at which time they consist of 50–150 cells. ESC measure approximately 14
μm while mouse ES cells are closer to 8 μm.[3]
Pluripotent
Embryonic stem cells are pluripotent, that is, they are able to differentiate into all derivatives of the
three primary germ layers: ectoderm, endoderm, and mesoderm. These include each of the more
than 220 cell types in the adult body. Pluripotency distinguishes embryonic stem cells from adult
stem cells found in adults; while embryonic stem cells can generate all cell types in the body, adult
stem cells are multipotent and can produce only a limited number of cell types.
Propagation
Additionally, under defined conditions, embryonic stem cells are capable of propagating themselves
indefinitely.[4] This allows embryonic stem cells to be employed as useful tools for both research
and regenerative medicine, because they can produce limitless numbers of themselves for
continued research or clinical use.
Usefulness
Because of their plasticity and potentially unlimited capacity for self-renewal, Embryonic stem cell
therapies have been proposed for regenerative medicine and tissue replacement after injury or
disease. Diseases that could potentially be treated by pluripotent stem cells include a number of
blood and immune-system related genetic diseases, cancers, and disorders; juvenile diabetes;
Parkinson's; blindness and spinal cord injuries. Other potential uses of embryonic stem cells include
investigation of early human development, study of genetic disease and as in vitro systems for
toxicology testing.
First clinical trial
On January 23, 2009, Phase I clinical trials for transplantation of oligodendrocytes (a cell type of the
brain and spinal cord) derived from ESC into spinal cord-injured individuals received approval from
the U.S. Food and Drug Administration (FDA), marking it the world's first ESC human trial.[5] The
study leading to this scientific advancement was conducted by Hans Keirstead and colleagues at the
University of California, Irvine and supported by Geron Corporation of Menlo Park, CA, founded by
Michael D. West, PhD. A previous experiment had shown an improvement in locomotor recovery in
spinal cord-injured rats after a 7-day delayed transplantation of ESC that had been pushed into an
oligodendrocytic lineage.[6] In the proposed phase I clinical study, about eight paraplegics will be
selected. However, the researchers are emphasizing that the injections are not expected to fully cure
the patients and restore all mobility. Based on the results of the rodent trials, researchers say
restoration of myelin sheathes, and an increase in mobility is probable. This first trial is mainly
testing the safety of these procedures and if everything goes well, it could lead to future studies that
involve people with more severe disabilities.[7]
1. Thomson et. al; Itskovitz-Eldor, J; Shapiro, SS; Waknitz, MA; Swiergiel, JJ; Marshall, VS; Jones, JM
(1998). "Blastocysts Embryonic Stem Cell Lines Derived from Sheep". Science 282 (5391): 1145–
1147. doi:10.1126/science.282.5391.1145. PMID 9804556.
2. "NIH Stem Cell Basics. What are embryonic stem cells?".
3. Thomson, James A.; Zwaka (10 February 2003). "Homologous recombination in embryonic stem
cells". Nature Biotechnology 21 (3): 319–321.
4. Ying et. al; Nichols, J; Chambers, I; Smith, A (2003). "BMP Induction of Id Proteins Suppresses
Differentiation and Sustains Embryonic Stem Cell Self-Renewal in Collaboration with STAT3". Cell 115
(3): 281–292. doi:10.1016/S0092-8674(03)00847-X. PMID 14636556.
5. "FDA approves embryonic stem cell study - CNN.com". January 23, 2009. Retrieved May 1, 2010.
6. Keirstead HS, Nistor G, Bernal G, et al. (2005). "Embryonic stem cell-derived oligodendrocyte
progenitor cell transplants remyelinate and restore locomotion after spinal cord injury". J. Neurosci.
25 (19): 4694–705. doi:10.1523/JNEUROSCI.0311-05.2005. PMID 15888645.
7. Steven Reinberg FDA OKs 1st Embryonic Stem Cell Trial